Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX -- Ignore unavailable to you. Want to Upgrade?

To: fred hayes who wrote (96)	2/20/2013 11:39:51 AM
From: mopgcw	Respond to of 184

appreciate your insights as always, obviously i agree, and was actually thinking of adding another slug here on this downdraft.

To: fred hayes who wrote (96)	2/20/2013 2:09:42 PM
From: scaram(o)uche	1 Recommendation Read Replies (1) \| Respond to of 184

Panel Chair was straight out of Twilight Zone. The traditional FDA view of new adjuvants and new cell platforms for the production of vaccines? (only the first being relevant here) Thou shalt go to hell and back, and then add 10 years. Imagine a lung surfactant, ten times pain in ass. That was the FDA of 1990...... honchos really go through agony re. new adjuvants. Adjuvants need to keep up and we can't leave the hoop jumping exclusively to deep-pocket pharmas. Some on the panel seemed almost offended that little DVAX would wander into the Realm.